Key features and details | |
Cat. No. | MABL-848 |
Name | Anti-CD27 mAbs |
Clone No. | AFD- RM27-3E5 |
From | Recombinant Antibody |
Isotype | Engineer antibody |
Application | IP, Neutralisation, FC |
Species Reactivity | Mouse |
Basic Information | |
Specificity | This antibody is specific for the extracellular domain of murine CD27, a TNF-receptor superfamily member. |
Alternative Name | TNFRS7; CD27 antigen; CD27L receptor; T-cell activation antigen CD27; Tumor necrosis factor receptor superfamily member 7 |
UniProt | P41272 |
Immunogen | This antibody was raised by immunising mouse with mouse CD27-human IgG1 Fc fusion protein. Isolated popliteal lymph node cells were then fused with P3U1 myeloma cells to produce stable hybridomas. |
Application Notes | This antibody recognises murine CD27, as confirmed by flow-cytometry and immunoprecipitation analysis (Sakanishi & Yagita, 2010), a member of the TNF-receptor superfamily. The interaction between CD27 and its ligand CD70, which is recognised by anti-CD70 antibody TAN 1-7 (Ab00816), is crucial to regulation of the survival and differentiation of T cells, B cells and NK cells. As a result, RM27-3E5 modulates multiple immune cell types. The original rat IgG2a version of RM27-3E5 did not deplete T cells, NKT or NK cells, but does enhance the proliferation of anti-CD3-stimulated splenic T cells (Sakanishi & Yagita, 2010). In murine models of melanoma, it promotes the persistence of tumour-specific CD8+ T cells within tumours, and reduces levels of PD-1 expression on CD8+ T cells (Roberts et al, 2010). Additionally, anti-CD27 reduces the proportion of FoxP3+ CD4+ T cells in tumours, and enhances the effector activity of IFNγ-secreting, tumour-infiltrating CD8+ T cells and NK cells (Roberts et al, 2010).Finally, anti-CD27 Ab treatment alters murine splenocyte cytokine production, significantly reducing IL-5 and IFN-γ synthesis, and increasing TNF-α production (Sumi et al, 2008). |
Antibody First Published | Sumi et al CD27 and CD70 do not play a critical role in the development of experimental allergic conjunctivitis in mice Immunology Letters, Volume 119, Issues 1–2, 15 August 2008, Pages 91-96 PMID：18579220 |
Note on publication | Describes the original generation of this antibody. |
COA Information （For reference only, actual COA shall prevail） | |
Size | 100 μg Purified antibody. |
Concentration | 1 mg/ml. |
Purification | Protein A affinity purified |
Buffer | PBS with 0.02% Proclin 300. |
Concentration | 1 mg/ml. |
Storage Recommendation | Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C. |
